Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- AOBC -10.2%, EXFO -1%
Other news:
- CARA -29% (announces top-line results from a Phase 2b trial of an oral tablet formulation of CR845 in patients with osteoarthritis of the knee or hip; Statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose)
- CIDM -26.4% (following conference call after the close on recent discovery for pancreatic cancer and business update)
- MBRX -24.2% (conference call to discuss recent new discovery for pancreatic cancer and business update)
- DEST -23.3% (following FY17 results from merger partner Orchestra Prémaman)
- RGR -4.2% (following AOBC earnings)
- ALKS -3.3% (announces preliminary topline results from ENLIGHTEN-1, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia)
- CBK -3% (CFO & COO Pete Michielutti resigns effective July 14 to accept another opportunity)
- CVM -2.1% (disclosed the FDA requested that three additional changes be made to Multikine Investigator Brochure submitted on June 2)
- PCRX -1.3% (determined to discontinue all future production of DepoCyt)
Analyst comments:
- VIPS -2% (downgraded to Hold from Buy at Deutsche Bank)
- WUBA -1.9% (downgraded to Underweight at Morgan Stanley)
- BLUE -1.4% (downgraded to Neutral from Buy at BTIG Research)